Dravet Syndrome clinical trials at UCSF
9 in progress, 6 open to eligible people
Dravet Syndrome is a rare genetic condition that causes seizures. UCSF is doing some clinical trials to find out if medicines can help. These studies are testing different drugs to see if they can control seizures in people with Dravet Syndrome. They want to learn more about the safety and effectiveness of these treatments for both children and adults.
A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome
open to eligible people ages 2-56
The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of seizures in children and adults with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS). Participants will receive their standard anti-seizure therapy, plus tablets of soticlestat. There will be scheduled visits and follow-up phone calls throughout the study.
San Francisco, California and other locations
A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome
open to eligible people ages 2-21
The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of convulsive seizures in children and young adults with DS. Participants will receive their standard antiseizure therapy, plus either a tablet of soticlestat or placebo for 16 weeks. A placebo looks just like soticlestat but will not have any medicine in it. Participants may continue treatment in an extension study, based on the extension study's entry criteria. Those that want to stop treatment will have a gradual dose reduction during 1 week and then be followed up for 2 weeks.
San Francisco, California and other locations
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome
open to eligible people ages 2-18
Stoke Therapeutics is evaluating the safety and tolerability of single and multiple ascending doses of STK-001 in patients with Dravet syndrome. Change in seizure frequency, overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.
San Francisco, California and other locations
EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome
open to eligible people ages 2 years and up
The purpose of this study is to evaluate the safety and efficacy of EPX-100 as adjunctive therapy in children and adult participants with Dravet Syndrome.
San Francisco, California and other locations
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
open to eligible people ages 12-65
The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.
San Francisco, California and other locations
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
open to eligible people ages 12-65
The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.
San Francisco, California and other locations
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
Sorry, in progress, not accepting new patients
This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
San Francisco, California and other locations
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
Sorry, accepting new patients by invitation only
Stoke Therapeutics is evaluating the long-term safety & tolerability of repeated doses of STK-001 in patients with Dravet syndrome who previously participated in studies of STK-001. Change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.
San Francisco, California and other locations
Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies
Sorry, in progress, not accepting new patients
This is a multicenter, prospective, 2-year observational study in infants and children with developmental and epileptic encephalopathies (DEEs). The DEE currently being investigated is SCN1A-positive Dravet Syndrome.
San Francisco, California and other locations
Our lead scientists for Dravet Syndrome research studies include Ernesto Gonzalez-Giraldo, MD Joseph Sullivan.
Last updated: